2020 – Page 2 – Car-T Central

Interim analysis of ZUMA-5: a phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory indolent non-hodgkin lymphoma

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Comparison of safety management costs across chimeric antigen receptor (CAR) T cell therapies in relapsed or refractory large B-cell lymphoma

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma – the Munich real life experience

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Tumor microenvironment and elevated IL6 are associated with severe toxicity in patients with LBL treated with axicabtagene ciloleucel

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Outcome of high-grade lymphoma patients treated with CD19 CAR-T – updated real-world experience in the UK

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Cost effectiveness of axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for adult patients with relapsed or refractory large B-cell lymphoma (rr lbcl) in the US

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

High-grade neurological toxicity following CD19 CAR-T therapy: outcomes from a single centre experience

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Retreatment of patients with refractory large B cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

CD19 CAR-T (axicabtagene ciloleucel) in patients with highly refractory diffuse large B-cell lymphoma – a single center experience

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]

Axicabtagene ciloleucel for the management of patients with diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma: an economic evaluation for Spain

Log In with AHPRA Professional Number Login Some areas of the CAR-T Central site may only be accessed by health care professionals. You are required to enter your full AHPRA […]